These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12709777)

  • 1. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
    Grillon C; Cordova J; Levine LR; Morgan CA
    Psychopharmacology (Berl); 2003 Aug; 168(4):446-54. PubMed ID: 12709777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
    Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
    J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
    Tizzano JP; Griffey KI; Schoepp DD
    Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats.
    Walker DL; Rattiner LM; Davis M
    Behav Neurosci; 2002 Dec; 116(6):1075-83. PubMed ID: 12492306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
    Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzodiazepines have no effect on fear-potentiated startle in humans.
    Baas JM; Grillon C; Böcker KB; Brack AA; Morgan CA; Kenemans JL; Verbaten MN
    Psychopharmacology (Berl); 2002 May; 161(3):233-47. PubMed ID: 12021826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
    Bueno AB; Collado I; de Dios A; Domínguez C; Martín JA; Martín LM; Martínez-Grau MA; Montero C; Pedregal C; Catlow J; Coffey DS; Clay MP; Dantzig AH; Lindstrom T; Monn JA; Jiang H; Schoepp DD; Stratford RE; Tabas LB; Tizzano JP; Wright RA; Herin MF
    J Med Chem; 2005 Aug; 48(16):5305-20. PubMed ID: 16078848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.
    Schreiber R; Lowe D; Voerste A; De Vry J
    Eur J Pharmacol; 2000 Jan; 388(2):R3-4. PubMed ID: 10666513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
    Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
    Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.
    Collado I; Pedregal C; Mazón A; Espinosa JF; Blanco-Urgoiti J; Schoepp DD; Wright RA; Johnson BG; Kingston AE
    J Med Chem; 2002 Aug; 45(17):3619-29. PubMed ID: 12166935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
    Linden AM; Greene SJ; Bergeron M; Schoepp DD
    Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm.
    Kehne JH; Cassella JV; Davis M
    Psychopharmacology (Berl); 1988; 94(1):8-13. PubMed ID: 2894703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man.
    Bitsios P; Philpott A; Langley RW; Bradshaw CM; Szabadi E
    J Psychopharmacol; 1999; 13(3):226-34. PubMed ID: 10512076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
    Ferris P; Seward E; Dawson GR
    J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.
    Baas JM; Mol N; Kenemans JL; Prinssen EP; Niklson I; Xia-Chen C; Broeyer F; van Gerven J
    Psychopharmacology (Berl); 2009 Jul; 205(1):73-84. PubMed ID: 19415242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
    J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?
    Nevins ME; Anthony EW
    J Pharmacol Exp Ther; 1994 Jan; 268(1):248-54. PubMed ID: 7905528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption.
    Joordens RJ; Hijzen TH; Olivier B
    Life Sci; 1998; 63(25):2227-32. PubMed ID: 9870708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats.
    Li X; Kaczanowska K; Finn MG; Markou A; Risbrough VB
    Neuropharmacology; 2015 Oct; 97():357-64. PubMed ID: 26002628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.